Medicxi Ventures Management (Jersey) Ltd
CIK 1715579
13F filing for Q2 2026・No. 6,940
- Holdings
- US$177.42M
- Quarter change
- −US$804.38M
- Entries
- 3
- Net bought (estimate)
- −US$808.71M
The quarter change is the holdings' value against the quarter before, price moves included — not what was bought or sold; each institution's page estimates that.
Net bought (estimate)
Each stock's change in shares at the quarter-end price, added up: a new position counts as bought, one sold out as sold, shares held long only. Splits are compared split-adjusted; corporate actions under a new CUSIP are not estimated. An estimate from the filings, not actual trades.
- New 0
- Sold out 1
- Cut 1
- Added 0
- Corporate actions 0
- Unchanged 2
Largest holdings
3 stocks worth US$177.42M, options and bonds left out.
| Stock | This quarter | Shares | Value | Weight |
|---|---|---|---|---|
| PHATHOM PHARMACEUTICALS INCCOM | Unchanged | 7,464,572 | US$80.99M | 45.65% |
| NAMSNEWAMSTERDAM PHARMA COMPANYORDINARY SHARES | Cut | 2,208,639 | US$74.85M | 42.19% |
| AURA BIOSCIENCES INCCOM | Unchanged | 3,039,892 | US$21.58M | 12.16% |
Sign in (free) to see its 3 largest holdings and its trades. Sign in
Filings
The quarter's original 13F filings (SEC).
- 13F-HRFiled August 4, 2026SEC ↗
13F covers long positions in US-listed securities only; the data is SEC's, filed within 45 days of the quarter's end.